![]() |
|
|
Vol. 20, Issue 19, 4225-4234, October 1, 2009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regulates Endothelial Cell–Cell Junction Integrity by Controlling the Trafficking of Transmembrane Junction Proteins



*Cellular Architecture and Dynamics, Institute of Biomembranes, Utrecht University, 3584 CH Utrecht, The Netherlands;
Molecular Biophysics, Debye Institute for Nanomaterials Science, 3584 CC Utrecht, The Netherlands; and
Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195
Submitted February 26, 2008;
Revised July 6, 2009;
Accepted July 30, 2009
Monitoring Editor: Vivek Malhotra
In endothelial cells specifically, cPLA2
translocates from the cytoplasm to the Golgi complex in response to cell confluence. Considering the link between confluence and cell–cell junction formation, and the emerging role of cPLA2
in intracellular trafficking, we tested whether Golgi-associated cPLA2
is involved in the trafficking of junction proteins. Here, we show that the redistribution of cPLA2
from the cytoplasm to the Golgi correlates with adherens junction maturation and occurs before tight junction formation. Disruption of adherens junctions using a blocking anti-VE-cadherin antibody reverses the association of cPLA2
with the Golgi. Silencing of cPLA2
and inhibition of cPLA2
enzymatic activity using various inhibitors result in the diminished presence of the transmembrane junction proteins VE-cadherin, occludin, and claudin-5 at cell–cell contacts, and in their accumulation at the Golgi. Altogether, our data support the idea that VE-cadherin triggers the relocation of cPLA2
to the Golgi and that in turn, Golgi-associated cPLA2
regulates the transport of transmembrane junction proteins through or from the Golgi, thereby controlling the integrity of endothelial cell–cell junctions.
Address correspondence to: Elsa Regan-Klapisz (E.E.Regan1{at}uu.nl).
Abbreviations used: cPLA2
, cytosolic PLA2 alpha; HUVEC, human umbilical vein endothelial cell; MAFP, methylarachidonyl fluorophosphonate; PLA2, phospholipase A2; VE-cadherin, vascular endothelial cadherin.